PubMed Health⌕ Search

Biomedical subjects

B Büki

Publications and source records attributed to B Büki.

39 records · Page 3Linked to original sources

Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.

In order to investigate pancreatic B-cell function in hepatic cirrhosis and to elucidate the role of porto-caval shunt-circulation in the development of hyperinsulinism and hyperglucagonemia in cirrhotic patients, blood glucose, plasma insulin and glucagon, and serum C-peptide concentrations were measured during OGTT in 11 control and 16 cirrhotic subjects as well as in 7 patients with prehepatic block secondary to thrombosis of the portal vein. Insulin and glucagon levels were significantly higher in the cirrhotic than in the control group (for insulin: p less than 0.01, less than 0.001, less than 0.01 and less than 0.05 at 0, 60, 90 and 120 min, respectively; for glucagon: p less than 0.01, less than 0.01, and less than 0.05 at 0, 30 and 60 min, respectively). Serum C-peptide levels were, however, similar in the two groups with the exception of the 30-min value, which was significantly lower in the cirrhotic group (p less than 0.05). Plasma insulin and glucagon concentrations in patients with prehepatic block were similar to those of the controls but significantly lower than the values found in cirrhotic patients (for insulin: p less than 0.05 at 0, 30, 60 min, respectively). Serum C-peptide levels of these patients were not significantly different either from the control values or from those obtained in the cirrhotic group. Accordingly, pancreatic B-cell secretion is not increased in hepatic cirrhosis. Hence, the hyperinsulinism is due to decreased heptic degradation of the hormone. Decreased degradation of both insulin and glucagon should be attributed mainly to parenchymal liver damage, rather than porto-systemic shunting.

Adolescent↗

Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study.

UNLABELLED: The outlook for patients with testicular germ cell cancer was dramatically improved by the introduction of cisplatin. Well-known side effects of cisplatin (nausea, vomiting, nephrotoxicity, myelosuppression) can be managed with preventive methods. The long life expectancy after this therapy draws attention to long-term side effects. The ototoxic side effects were scarcely studied, although nowadays, they can be a dose-limiting side effect of cisplatin. PATIENTS AND METHODS: As the literature shows, the ototoxic side effects of cisplatin have been studied mostly by conventional methods. The authors used transiently evoked otoacoustic emissions to determine whether the administration of 20 mg/m2 body surface cisplatin daily (in combination with other antitumor drugs) for 5 days alters the amplitude of the transient otoacoustic emission. RESULTS: The results did not show any significant amplitude change after 20 mg/m2 cisplatin daily for 5 days, in contrast with other studies that described a broad frequency reduction of the emission amplitude in 30-86% of cases treated with 100 mg/m2 of cisplatin for 1 day. CONCLUSION: The authors suggest that between similarly effective regimens, those containing lower daily cisplatin doses should be used.

Antineoplastic Agents↗

Auditory brainstem potentials in uraemia.

Evoked response audiometry was carried out to assess the viability of the auditory pathway in haemodialysed patients. The latency of the waves III and V and I-V interpeak latencies were significantly longer in the renal patients compared to the control group. The I-V interpeak latency was longer in 8 of our 13 patients than the upper limit (4.38 ms) in our laboratory. The possible cause for the central auditory dysfunction may be multifactorial, including the effect of metastatic calcifications, repeated occurrence of disequilibrium syndrome, or some small, molecular, toxic, metabolic substance. The significance of the different factors may vary among different haemodialysis centres.

Adult↗